Journal of American Physicians and Surgeons | Winter 2021
On Oct 29, 2021, the Food and Drug Association (FDA) extended its Emergency Use Authorization (EUA) for the PfizerBioNTech “vaccine” to be given to reduce serious COVID-19 infections in children aged 5 through 11 years. The FDA provided little evidence for its decision except for a minimal sized “immunobridging” study, which incorrectly considered blood antibody levels to be the same thing as immunity to the SARS-CoV-2 virus, the cause of COVID-19. It is not—especially when using an mRNA “vaccine” that is demonstrably no longer working in the older age groups.
The Pfizer COVID-19 mRNA vaccine is not really a “vaccine” in the true sense of the word. It does not provide longterm immunity like the existing vaccines for measles, polio, chickenpox, and smallpox. Rather, it is an experimental nucleic
acid preparation that is associated with rare but catastrophic side effects in individuals aged 12 and older. The administration of the Pfizer-BioNTech and other mRNA “vaccines” for children aged 5–11 should be a decision between physicians and parents. Alternatively, successful early drug treatments for COVID-19 are available.
